Incyte (INCY, $51.65) was a top loser over the last three months, falling -1 to $51.65 per share. A.I.dvisor analyzed 916 stocks in the Biotechnology Industry for the 3-month period ending April 23, 2024, and found that of them (5) exhibited an Uptrend while of them (4) demonstrated a Downtrend.